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Abstract Bone morphogenetic proteins (BMPs) are well-established agents for inducing orthotopic and ectopic
bone formation. However, their clinical usefulness as regenerative agents may be limited by a short in vivo half-life and
low specific activity. BMP gene therapy is an alternative route for exploiting the bone-inductive activity of this class of
molecules. To test the feasibility of this approach, we examined the osteogenic activity of AdCMV-BMP7, an
adenovirus containing BMP7 cDNA under control of the CMV promoter that was constructed using Cre/lox recombi-
nation (Hardy et al. [1997] J. Virol. 71:1842–1849). Adenovirus vectors were shown to readily infect a wide variety of
cell types in vitro including osteoblasts, fibroblasts, and myoblasts. COS7 cells transduced with AdCMV-BMP7
produced high levels of BMP-7 (approximately 0.5 mg/106 cells). Furthermore, transduction of C2C12 murine myoblast
cells with AdCMVBMP-7 suppressed the muscle phenotype and induced in vitro osteoblast differentiation. To test its
in vivo biological activity, AdCMV-BMP7 was mixed with a bovine bone-derived collagen carrier (108 plaque-forming
units virus/site) and was implanted into mouse muscle and dermal pouches. In both cases, an ossicle containing cortical
and trabecular bone and a clearly defined marrow cavity formed at the site of virus implantation within 4 weeks. These
data demonstrate that AdCMV-BMP7 transduced cells produce biologically active BMP-7 both in vitro and in vivo and
show that gene therapy by direct viral transduction using a virus/matrix implant may be a viable route for stimulating
bone regeneration. J. Cell. Biochem. 78:476–486, 2000. © 2000 Wiley-Liss, Inc.
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Use of recombinant bone morphogenetic pro-
teins (BMPs) for bone regeneration represents
one of the most promising emerging therapies
for bone regeneration and is a viable alterna-
tive to autologous and homologous bone grafts.
These molecules have the unique ability to al-
ter the differentiation pathway of mesenchy-
mal cells toward chondrogenic and osteogenic
lineages with the ultimate induction of endo-
chondral bone at ectopic or orthotopic sites.
Recombinant BMP2 and 7 have been shown to
induce healing of segmental defects in a num-
ber of species including nonhuman primates
[Yasko et al., 1992; Gerhart et al., 1993; Cook
et al., 1994a, 1994b, 1995]. The successful use
of BMPs to heal bony defects in humans has
also been described [Bulstra, 1998; Geesink,
1999]. Although BMP protein therapy is well
on the way toward being a clinically useful
procedure, it is already apparent that BMP-
containing devices fail in a certain percentage
of cases [Bulstra, 1998]. Reasons for failure
may be related to a lack of optimal matrixes for
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controlled, sustained BMP delivery at the site
of implantation, short biological half-life, and
inability of recombinant molecule presentation
after implantation to mimick the route of ad-
ministration in vivo by a BMP-producing cell.
Thus, although recombinant BMPs are prom-
ising therapeutic agents, there is still clearly a
need for additional approaches to their use in
bone regeneration.
Gene therapy was originally conceived as a
means of correcting hereditary disorders
[Friedmann, 1996]. However, more recent
work is applying the same gene transfer tech-
nologies to situations where there is no under-
lying genetic defect, but, instead, a need to
produce sustained amounts of a biologically ac-
tive molecule. Some representative examples of
this type of gene therapy include the introduc-
tion of cytotoxic or cystostatic genes into arte-
rial smooth-muscle cells as a potential treat-
ment for restenosis [Feldman et al., 1996], gene
transfer of tumor suppressor genes to treat
hepatocellular carcinoma [Anderson et al.,
1998], and induction of genes into brain tissue
to alter neurotransmittter/receptor levels as a
potential treatment for epilepsy [O’Connor et
al., 1997].
Such studies suggest that a further refine-
ment of BMP therapy might be the use of gene
transfer technology to convert connective
tissue/stem cells at a designated localized site
for bone regeneration into minireactors to pro-
duce sustained levels of BMPs. Unlike protein
therapy, in which effects of the recombinant
BMP are limited by protein degradation and
inactivation at the site of application, gene
transfer would be predicted to elicit sustained
BMP production and more complete repair of
the bony lesion. Adenovirus vectors have sev-
eral characteristics making them well suited to
this type of gene therapy, including the follow-
ing.
1. Extremely high transduction efficiencies
that are several orders of magnitude more
efficient than traditional naked DNA or
liposome-mediated gene transfer methods.
2. Ability to accommodate large (up to 7.5 kb)
cDNAs.
3. Growth to high titers.
4. Broad host-cell range allowing efficient in-
fection of a wide variety of cell types.
5. Low pathogenicity in humans. And
6. Inability to integrate into the host genome,
which avoids potential problems associated
with insertional mutagenesis [Horwitz,
1990; Jaffe et al., 1992; Kirshenbaum et al.,
1993; Le Gal La Salle et al., 1993; Ragot et
al., 1993; Zabner et al., 1993; Chen et al.,
1994].
The latter point is particularly important for
regenerative therapies because the viral ge-
nome is not replicated with host cells and,
hence, will eventually be lost by dilution and
cell attrition. Although this may generally pre-
clude use of adenovirus vectors for correcting
monogenic hereditary disorders, it may actu-
ally be beneficial for bone regeneration, where
only a finite period of transgene expression is
desirable. Finally, adenovirus vector develop-
ment is a rapidly evolving and improving tech-
nology. For example, new methods for vector
construction using Cre/lox-mediated recombi-
nation have greatly shortened the time re-
quired for viral vector creation relative to the
current widely used method of homologous re-
combination [Hardy et al., 1997].
There are two conceivable routes for the lo-
calized introduction of recombinant viruses to
the desired site for bone regeneration: (1) virus
is either directly implanted at the regeneration
site where it infects neighboring cells, which
begin producing recombinant protein (direct
gene therapy); or (2) bone cell precursors are
harvested, expanded, and infected with virus
in vitro, followed by implantation to the regen-
erative site (indirect gene therapy). In either
case, virus must be localized to the site tar-
geted for bone formation either by adsorption
to a suitable carrier or by containment and
expression by transplanted cells. This is most
readily accomplished using a space-filling ma-
trix. Three recent reports described the induc-
tion of bone in ectopic and orthotopic sites us-
ing immortalized cell lines or marrow cells
infected in vitro with adenoviruses expressing
BMP2 or 4 that were subsequently injected
into animals [Lieberman et al., 1998; Riew et
al., 1998; Lou et al., 1999]. In addition, direct
injection of an adenovirus expressing BMP2
into muscle was reported to induce ectopic bone
[Musgrave et al., 1999]. However, no previous
work has shown induction of bone by direct
viral transduction from a carrier matrix in
vivo. Although the approach of implanting ex
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vivo transduced cells holds promise, a direct in
vivo gene transfer strategy obviates the need to
obtain host cells from marrow or other sites
and the ensuing morbidity from these proce-
dures.
The present study was undertaken to test
the feasibility of using direct gene therapy with
a BMP7-expressing adenovirus adsorbed to a
carrier matrix as a means of inducing bone
formation. AdCMV-BMP7, a recombinant ade-
novirus containing BMP7 cDNA under the con-
trol of a viral promoter, was constructed using
Cre/lox recombination [Hardy et al., 1997].
This virus induced the expression of functional
BMP7 when transduced into cultured cells and
stimulated osteoblastic differentiation of C2C12
myoblasts in vitro. AdCMV-BMP7 was mixed
with a bovine bone-derived collagen matrix and
was shown to induce ectopic bone formation
after implantation into subcutaneous and in-
tramuscular sites in mice.
METHODS
Adenovirus Construction
AdCMV-BMP7 was constructed by Cre/lox
recombination [Hardy et al., 1997] using re-
agents and protocols provided by Dr. Steven
Hardy (Cell Genesys, Inc., Foster City, CA).
Briefly, the method involves cloning full-length
BMP7 (aka OP-1) cDNA (a gift from Dr. Her-
man Oppermann, Creative Biomolecules, Hop-
kinton, MA) into the BamH1 and Kpn1 sites of
shuttle plasmid, pAdlox. This plasmid was co-
transfected with psi5 adenovirus into CRE8
cells. Primary lysates were collected after 5
days and were used to reinfect CRE8 cells. The
plaque assay method was used to purify virus
from this secondary lysate. Each lysate was
screened for the presence of BMP7 insert using
polymerase chain reaction. Positive plaques
were amplified in 293 cells and were purified
by CsCl gradient ultracentrifugation. Purified
virus was stored in 10% glycerol/phosphate-
buffered saline and titered using a plaque for-
mation assay. Normal titers were approxi-
mately 1010 plaque-forming units (pfu)/ml.
AdRSVntlacZ, a recombinant adenovirus con-
taining the bacterial b-galactosidase gene to
which a nuclear localization sequence has been
added [Roessler et al., 1993], was obtained
from the University of Michigan Vector Core.
Cell Culture
MC3T3-E1 cells [Sudo et al., 1983] were cul-
tured in ascorbic acid–free a-modified Eagle’s
medium containing 10% fetal bovine serum
(FBS), and 1% pen-strep as previously de-
scribed [Franceschi and Iyer, 1992]. C2C12
cells [Yaffe and Saxel, 1977], a gift from Dr.
Daniel Goldman (University of Michigan, Ann
Arbor, MI), were maintained in Dulbecco’s
Modified Eagle Medium (DMEM), 10% fetal
bovine serum, and 1% pen/strep. Human gin-
gival and pulp fibroblasts, obtained as surgical
waste from the University of Michigan Dental
School Clinic, were also maintained in DMEM,
10% FBS. Procedures for collection of human
cells were in compliance with the Internal Re-
view Board for Research on Human Subjects of
the University of Michigan.
For in vitro transduction of cell lines, adeno-
virus at the desired titer was added to cells in
serum-free a-MEM. After 4 h, FBS was added
to a final concentration of 2% and medium was
kept on cells for an additional 24 h. Cells were
then refed with complete medium containing
10% FBS, 50 mg/ml ascorbic acid, 10 mM
b-glycerol phosphate, and fed at 48-h intervals
for the duration of the experiment.
Western Blot Quantitation of BMP7
Conditioned medium from virally trans-
duced COS7 cells was prepared by incubation
in serum-free MEM-a for 24 h. Dialyzed lyoph-
ilized samples were dissolved in 1x sodium do-
decyl sulfate polyacrylamide gel electrophore-
sis (SDS-PAGE) loading buffer (2% SDS, 2 M
urea, 10 mM dithiothreitol, 10% glycerol, 10
mM Tris HCl, 0.002% bromophenol blue), frac-
tionated by SDS-PAGE on 10% gels and elec-
trophoretically transferred to a nitrocellulose
membrane (Schleicher & Schuel, Keene, NH).
Anti-BMP7 antibody, a gift from Dr. Marc
Charette (Creative Biomolecules), was used at
a dilution of 1:1,000. A second antibody (horse-
radish peroxidase–conjugated goat anti-rabbit
IgG) was used at a dillution of 1:10,000. Block-
ing and reaction with antibodies was conducted
as previously described [Winnard et al., 1995].
Immunoreactivity was determined using the
ECL chemiluminescence reaction (Amersham).
Assays
Alkaline phosphatase activity was measured
in cell layers as previously described using a
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p-nitrophenylphosphate substrate [Manolagas
et al., 1981], and DNA was determined accord-
ing to the method of Schneider [Schneider,
1957]. To quantify mineralization in C2C12
cultures, cell layers were extracted in 15% tri-
chloroacetic acid and assayed for total phos-
phate using the method of Heinonen and Lahti
[Heinonen and Lahti, 1981]. b-Galactosidase
was measured with a commercially available
kit (Tropix, Inc., Bedford, MA) using reagents
and protocols provided by the manufacturer.
In Vivo Analysis of Osteogenic Activity
All procedures were approved by the Univer-
sity Committee on Use and Care of Animals
and were in compliance with State and Federal
laws. Adenovirus was mixed with guanidine-
extracted demineralized bovine bone powder
(prepared as described by Sampath et al. [Sam-
path et al., 1990]) and was implanted into ei-
ther subcutaneous or intramuscular sites in
CD-1 mice. Normally, two subcutaneous and
two intramuscular implants were placed in
each animal. To facilitate comparisons, one
control (AdRSVntLacZ virus implant) and one
experimental (AdCMV-BMP7 virus implant)
was placed in each site in a given animal. All
operations were performed with animals under
anesthesia achieved by inhalation of methoxy-
flurane (Mallinkrodt Veterinary, Mundelein,
IL). Midlongitudinal skin incisions 1 cm long
were made on the dorsal surface of CD-1 mice,
and subcutaneous pockets were formed by
blunt dissection. A single transplant contain-
ing 5 mg of carrier and 107–108 pfu virus was
placed into each pocket and the wound was
closed with surgical staples. Alternatively, a
1-cm incision was made on the lateral aspect of
both thighs. A 0.5-cm slit was then made in
each quadriceps to create a pocket into which
the viral preparation was inserted. The trans-
plants were recovered 4 weeks after transplan-
tation and were fixed and partially decalcified
for 2 days in Bouin’s solution (Sigma, St. Louis,
MO). The transplants were then transferred to
70% ethanol and were embedded in paraffin.
Sections of 5 mm were deparaffinized, hy-
drated, and stained with hematoxylin and eo-
sin.
Statistical Analysis
Where indicated, experimental data are re-
ported as means 6 SDs of triplicate samples.
RESULTS
Adenovirus Vectors Transduce a Range of Cell
Types Relevant to Craniofacial Regeneration
To assess the degree to which adenovirus
vectors can transduce cells of interest for
craniofacial regeneration, four representative
cells lines expressing osteoblastic (MC3T3-E1
preosteoblasts), fibroblastic (from gingival and
pulp biopsies), and muscle (C2C12 myoblasts)
phenotypes were treated with AdRSVntLacZ,
an adenovirus expressing bacterial b-galacto-
sidase containing a nuclear localization se-
quence. As shown in Figure 1 and Table I, all
cells were readily transduced by this vector,
although the multiplicity of infection (m.o.i.)
(pfu/cell) necessary to achieve high transduc-
tion varied between cell lines. Thus, pulp fibro-
blasts were more readily transduced (m.o.i. for
90%–100% transduction 5 125–250) than the
other cell types (m.o.i. for 90–100% transduc-
tion 5 500–1000). Virally transduced cells ex-
hibited no obvious morphological changes.
Virus-derived b-galactosidase activity could be
detected in MC3T3-E1 cells throughout the
3-week culture period examined. However,
when normalized to cell DNA, b-galactosidase
activity decreased by 90% (Fig. 2A). This de-
cline was mainly caused by the proliferation of
nontransduced cells in the culture that became
an increasingly larger percent of the total cell
population with time (result not shown). To
test whether introduction of virus could alter
the differentiated phenotype of osteoblasts,
MC3T3-E1 cells were mock-infected or trans-
duced with AdRSVntlacZ at an m.o.i. of 500
and were examined for ability to form a miner-
alized extracellular matrix as would be ex-
pected if cells retained their phenotype after
viral transduction. As shown in Figure 2B,
both mock-infected and virally transduced cells
mineralized to the same extent, indicating that
expression of viral genes does not interfere
with the differentiation process.
Measurement of the Release of Adenovirus from
a Bovine Bone Matrix Carrier
As a prerequisite to in vivo viral transduc-
tion experiments, we sought suitable carriers
for delivering virus to tissues. As noted above,
a carrier matrix is necessary to localize the
virus to a specific site and to serve as a suitable
substrate for cellular invasion. Our initial ef-
forts focused on a carrier composed of
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guanidine-extracted demineralized bovine
bone powder used for delivery of recombinant
BMPs [Sampath et al., 1990]. AdRSVntlacZ in
a 10% glycerol stock solution was mixed with
the lyophilized matrix and added to cultures of
MC3T3-E1 preosteoblast cells. After 48 h, the
number of cells with nuclear b-galactosidase
staining was scored and compared with cells
exposed to the same viral titer added directly to
the culture medium. The carrier did not affect
adenovirus transfection efficiency, indicating
that the virus was able to freely diffuse from
the matrix (result not shown).
Construction and Testing of an Adenovirus
Expressing BMP-7
AdCMV-BMP7, an adenovirus expressing
mouse BMP7 under control of a cytomegalovi-
rus promoter, was constructed using Cre/lox
recombination as described in the Methods sec-
tion. The resulting virus was plaque purified
and titered before use. Two criteria were used
to assess whether this virus could direct the
synthesis of functional BMP7 protein: (1) virus
was used to transduce COS7 cells in culture,
and the conditioned medium from these cells
Fig. 1. In vitro transduction of cell lines with an adenovirus expressing bacterial b-galactosidase. Cell lines were
transduced with the indicated titers of AdRSVntlacZ, a recombinant adenovirus containing the bacterial lacZ gene
under control of an SV40 promoter. After 48 h, cells were stained for nuclear b-galactosidase activity. Cell lines:
MC3T3-E1 preosteoblasts; human gingival fibroblasts; human dental pulp fibroblasts, C2C12 myoblasts.
TABLE I. In Vitro Viral Transduction of Cell Linesa
Viral titer
(m.o.i.)






0 0 0 0 0
125 35 6 2 44 6 4 92 6 5 38 6 3
250 63 6 5 82 6 7 99 6 2 79 6 2
500 84 6 8 98 6 2 100 6 0 92 6 4
1,000 96 6 2 100 6 0 100 6 0 98 6 2
aCells were transduced with the indicated titer of AdRSVnt-LacZ and stained for b-galactosidase activity after 48h. Total and
b-galactosidase-positive cells were then counted. m.o.i., multiplicity of infection.
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was analyzed for the presence of immunoreac-
tive BMP7; (2) the ability of virus to induce the
transdifferentiation of myoblasts to osteoblasts
in vitro was examined in the C2C12 myoblast
cell line. Figure 3 shows a Western blot of con-
ditioned medium from COS-7 cells transduced
with either control virus (AdRSVntlacZ) or
AdCMV-BMP7 that was probed with an anti-
BMP7 antibody. AdCMV-BMP7-transduced
cells clearly produced immunoreactive protein
that exhibited the same electrophoretic mobil-
ity as purified recombinant BMP7 on reduced
and nonreduced gels. Using these Western blot
data and correcting for sample concentration
after lyophilization and resuspention, we esti-
mate that COS-7 cells transduced with
AdCMV-BMP7 at an m.o.i. of 50 produced ap-
proximately 0.5 mg BMP7/106 cells.
The results shown in Figure 4 document the
responsiveness of C2C12 myoblasts to AdCMV-
BMP7 transduction. Other investigators previ-
ously showed that recombinant BMP2 stimu-
lates the transdifferentiation of these cells
from myoblasts to osteoblasts [Katagiri et al.,
1994]. Because BMP7 and BMP2 share com-
mon receptors (i.e., BMPR1A/B [Baker and
Harland, 1997]), we considered it likely that
osteoblastic differentiation could be induced in
these cells if AdCMV-BMP7 transduction re-
sulted in the production of functional BMP7
protein. Cells were transduced with either con-
trol virus (AdRSVntlacZ) or AdCMV-BMP7
and cultured under conditions conducive to os-
teoblast differentiation and mineralization
(i.e., in medium containing ascorbic acid and
b-glycerol phosphate). AdCMV-BMP7 at an
m.o.i. of 500 maximally stimulated the osteo-
blast marker, alkaline phosphatase, after 8
days in culture (Fig. 4A). Time course studies
revealed that the response to virus in terms of
either induction of alkaline phosphatase (Fig.
4B) or mineralization (Fig. 4C) required at
least 6 days and continued to increase through
day 10. AdCMV-BMP7 also dramatically al-
tered cell morphology (Fig. 4D). Control cul-
tures retained a myotube phenotype, whereas
cells in the AdCMV-BMP7-treated cultures as-
sumed a more rounded appearance and formed
clearly defined mineralized nodules. These re-
sults are very similar to those reported for
C2C12 cells treated with BMP2 protein and
clearly indicate that viral transduction elicits
the synthesis of biologically active BMP.
In Vivo Osteogenic Activity of AdCMV-BMP7
To test whether direct gene transfer of
AdCMV-BMP7 into soft tissues of mice can in-
duce ectopic bone formation, adenovirus (2.5 3
107 pfu/implant) was mixed with guanidine-
extracted demineralized bovine bone powder
and implanted into subcutaneous or intramus-
cular sites of CD-1 mice. Control implants con-
tained the same titer of AdRSVntlacZ. Virus
implants were removed for histological analy-
sis after 4 weeks. AdCMV-BMP7 formed bone
at subcutaneous (six positives/seven implants)
Fig. 2. Adenovirus infection does not alter the in vitro differ-
entiation of preosteoblast cells. MC3T3-E1 cells were plated
and transduced with 1,000 pfu/cell AdRSVntlacZ (open circles)
or exposed to the transduction conditions in the absence of
virus (closed circles) as described in the Methods section. Cells
were then transferred to differentiation medium and examined
at the times indicated for b-galactosidase activity (A) or matrix-
associated mineral phosphate (B).
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and intramuscular sites (seven positives/seven
implants). In no case did control implants elicit
an osteogenic response at either implant site.
Representative histological sections are shown
in Figure 5. Ossicles had a well-defined perim-
eter of cortical bone with trabeculae and an
obvious marrow cavity containing hematopoi-
etic cells as well as fatty marrow surrounding
residual carrier (Fig. 5A,C). An examination
under higher magnification revealed that min-
eralized areas contained osteocytelike cells
within a bonelike ECM (Fig. 5E,F). In contrast,
control implants (Fig. 5B,D) showed residual
carrier matrix and infiltration with inflamma-
tory cells, but no evidence of bone formation.
DISCUSSION
The use of gene therapy to stimulate bone
regeneration represents a novel use of gene
transfer technology, the goal of which is to alter
levels of naturally occurring regenerative mol-
ecules to elicit a therapeutic response. Unlike
traditional gene therapies designed to correct
underlying genetic disorders, this approach
seeks to enhance a natural reparative response
by supplementing the regenerative site with
additional therapeutic molecules. In this re-
port, we describe the in vitro and in vivo bio-
logical activity of an adenovirus expressing
BMP7. Cells transduced with AdCMV-BMP7
in vitro produced immunoreactive BMP that
was electrophoretically indistinguishable from
recombinant protein. Furthermore, this virus
could induce the transdifferentiation of C2C12
myoblasts into osteoblastlike cells in vitro.
When mixed with a bovine bone-derived colla-
gen carrier and implanted into CD-1 mice,
AdCMV-BMP7 induced ectopic bone formation
at both intramuscular and subcutaneous sites.
There are several hurdles that must be over-
come for regenerative gene therapy to be suc-
cessful:
1. Efficient methods must be developed for the
localized introduction of foreign genes into
target cells with a minimal host immune
response.
2. Transferred genes must be expressed at ad-
equate levels and for a sufficient time to
effect a regenerative response, but must be
inactivated once the therapeutic response
has been achieved.
3. Viral vectors must be shown to safely infect
the cells of interest with minimal side ef-
fects.
Adenovirus vectors are among the most effi-
cient ways of delivering DNA to cells. We de-
tected a clear osteoinductive response with viral
titers as low as 107 pfu/implant (approximately
60 pg DNA). In contrast, although induction of
bone in a nonunion fracture model has been
reported using direct transfer of plasmid DNA
encoding BMP4 and PTH [Fang et al., 1996;
Bonadio et al., 1999], at present this mode of
Fig. 3. In vitro production of BMP7 by COS-7 cells transduced
with AdCMV-BMP7. An adenovirus expressing BMP7 under
control of the CMV promoter was constructed by Cre/lox re-
combination as described in the Methods section. COS-7 cells
were transduced with the indicated titer of AdRSVntlacZ (ln 1,
2) or AdCMV-BMP7 (lanes 3, 4). After 24 h, cells were trans-
ferred to serum-free medium and incubated for an additional
24 h. Medium was dialyzed, concentrated by lyophilization,
and aliquots were analyzed by Western blotting with anti-
BMP7 polyclonal antibody. Lanes 5 and 6 contain 300 ng of
purified, recombinant BMP7. Samples in lns. 1-5 were reduced
with 2 mM dithiothreitol (DTT) before electrophoresis.
482 Franceschi et al.
Fig. 4. In vitro induction of osteoblast differentiation by trans-
duction of C2C12 myoblasts with AdCMV-BMP7. A: Effect of
viral titer on alkaline phosphatase induction. C2C12 cells were
transduced with the indicated titer of AdCMV-BMP7 (closed
circles) or AdRSVnt lacZ (open circles) and grown in differen-
tiating medium. Alkaline phosphatase activity was measured
after 8 days. B, C: Time course of alkaline phosphatase induc-
tion and mineralization. C2C12 cells were transduced with 500
pfu/cell AdRSVntlacZ (open circles) or AdCMV-BMP7 (closed
circles). Cells were harvested at the times indicated for mea-
surement of alkaline phosphatase (B) and total mineral phos-
phate (C). D: Cell morphology. C2C12 cells were treated as
described in (B) and viewed under phase contrast after 12 days.
One control sample (left panel, AdRSVntlacZ) was stained for
b-galactosidase activity. Original magnification: 3100.
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gene transfer is extremely inefficient. Amounts
of plasmid DNA used to induce bone in these
studies were in the range of 50–100 mg, ap-
proximately 109 times more DNA than was
used in our virus transduction experiments.
Adenoviruses and, to a lesser extent, naked
DNA, are known to elicit a host immune re-
sponse [Wu et al., 1990; Orkin and Motulsky,
1995]. Immune rejection of gene therapy
agents may severely limit the clinical utility of
Fig. 5. In vivo bone formation. AdCMV-BMP7 (2.5 3 107
plaque-forming units) or control virus (AdRSVnt lacZ) in a
guanidine-extracted, demineralized bovine bone matrix carrier
was implanted into subcutaneous or intramuscular sites in
CD-1 mice as described in the Methods section. After 4 weeks,
implants were harvested for histological analysis. A: AdCMV-
BMP7, subcutaneous implant. This section shows a well-
defined ossicle (arrow) with unresorbed carrier matrix in the
center (c) surrounded by marrow. Original magnification: 320.
E: Higher magnification (3125) of the lower right corner of the
section in (A) showing cortical bone with clearly delineated
osteocytes (arrow) as well as hematopoietic and fatty marrow.
C: AdCMV-BMP7, intramuscular implant. The ossicle shown in
this section (arrow) had a morphology similar to that formed at
the subcutaneous site. Muscle adjacent to the virus implant is
also apparent (m). Original magnification: 320. F: Higher mag-
nification (3125) of the right side of the section in (C) showing
cortical bone with clearly delineated osteocytes (arrow) as well
as hematopoietic and fatty marrow. B, D: Subcutaneous and
intramuscular implants with control virus showing collagen
carrier, but no bone formation. Possible inflammation and cell
proliferation is apparent around the collagen carrier. Original
magnification: 320.
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the current generation of vectors. In the case of
the replication-deficient adenoviruses used in
the present study, expressed viral coat proteins
are the major immunogens that are known to
cause acute immune responses in vivo. How-
ever, it is likely that second-generation adeno-
viral vectors in which most of the viral genome
has been deleted (so-called gutted vectors) may
be able to at least in part overcome this prob-
lem [Amalfitano et al., 1996].
In this first report, we have not examined the
persistence of active AdCMV-BMP7 in trans-
duced cells in vivo. Thus, we do not yet know
whether the amount of BMP7 secreted or bone
formed by virus would increase with time
rather than plateau or regress, yet such infor-
mation is clearly critical for assessing the util-
ity of this approach for bone regeneration. Fur-
thermore, bone formation was only examined
at ectopic sites in vivo, yet therapeutic regen-
eration would normally be associated with ex-
isting bone where the mechanism and kinetics
of bone formation would likely be very differ-
ent. Detailed time course and dosing studies at
both ectopic and orthotopic sites will be re-
quired to assess the persistence of the response
to AdCMV-BMP7 transduction. Although it is
unlikely that the replication-defective adenovi-
rus used in this study could recombine with a
wild-type viral genome and propagate, there is
good evidence that viral gene expression can be
detected in transduced cells for several weeks
to months [Kass-Eisler et al., 1993]. Thus, per-
sistent viral expression of BMP7 could be tak-
ing place in our system. If so, it may be neces-
sary to use an adenovirus containing a
regulated promoter to control transgene ex-
pression.
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